subject: Macular Degeneration - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise [print this page] Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
The industry analysis specialists new report, Macular Degeneration Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global macular degeneration market. The report identifies the key trends shaping and driving the global macular degeneration market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular degeneration sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts.
Scope
The report analyzes market opportunities and challenges for the global macular degeneration market. Its scope includes
- Annualized global macular degeneration market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data provids a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include as VEGF targetors, angiogenesis inhibitors, photosensitizers, antioxidants, C5 inhibitors, choroidal neovascularization inhibitors, multi-kinase angiogenesis inhibitors, tyrosine kinase inhibitiors, FKBP12 binders, mTOR inhibitors, and visual cycle inhibitors.
- Analysis of the current and future market competition in the global macular degeneration market. Key market players covered are Alcon Inc., Miravant Pharmaceuticals, Novartis AG, BioInvent International AB, MacuSight, Inc., Ophthotech Corporation, Acucela Inc., Alexion Pharmaceuticals Inc., Inotek Pharmaceuticals, Inc., Jerini AG, Neurotech Usa, Inc., Oxford BioMedica, sanofi-Aventis, Paloma Pharmaceuticals, Inc., Pfizer Inc., PhiloGene Inc., pSivida Corporation, Resolvyx Pharmaceuticals, Inc., Targa Therapeutics Corp., and Tracon Pharma Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with macular degeneration.
